The first doses of the RNA vaccine should be delivered in the fourth quarter of 2021.
This is a breath of fresh air for the Global Alliance for Vaccines and Immunization (GAVI) faced with a shortage of doses.
Gavi announced Tuesday that it has signed an advance purchase agreement with Moderna for its COVID-19 RNA vaccine.
The first doses of the RNA vaccine are expected to be delivered in the fourth quarter of 2021, “with a total of 34 million doses available in 2021 and up to 466 million doses in 2022,” Gavi said in a statement released on Monday.
Covax, whose main supplier remains AstraZeneca has already shipped more than 49 million vaccines to 121 countries and territories.
The Vaccine Alliance has been facing a shortage of doses in recent months due to a ban on the export of AstraZeneca vaccine by India, its main supplier.
India is facing a resurgence of the disease, which has prompted it to redirect all production to its own population.
ARD/te/lb/as/APA